Crizotinib is active as second-line therapy against MET-mediated resistance to alectinib in anaplastic lymphoma kinase (ALK)-rearranged non–small-cell lung cancer and can be used in combination.
Repeat molecular analyses including assessment of MET amplification can help guide therapy in ALK-positive non–small-cell lung cancer. READ ARTICLE
Clinical Lung Cancer DOI:10.1016/j.cllc.2021.04.008
Authors: Jingran Ji, Anupam Mitra, D. Ross Camidge, Jonathan W. Riess
Several anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors have been developed for the treatment of EML4-ALK-rearranged non-small-cell lung cancer, with the newer generation agents brigatinib, alectinib and lorlatinib showing pronounced central nervous system activities. Intracranial efficacy is an important feature for these agents, as metastatic lesions frequently occur in the central nervous system in the ALK-positive setting. Here, we report on an updated case of a patient who received her diagnosis in 2005 and has had disease progression with new lesions on six occasions over the last 8 years. During the first two progressions, only local recurrence was observed. After that, the lungs stayed clear and the patient progressed exclusively in the brain and spinal cord. Initial treatments consisted of chemotherapy and radiotherapy. In 2012, ALK-directed targeted therapy became available, and crizotinib was administered. The treatment was switched to brigatinib 3 years later be..... READ ARTICLE
Anti-Cancer Drugs
DOI:10.1097/CAD.0000000000000800
Authors: Hochmair, Maximiliana; Weinlinger, Christopha; Prosch, Helmut
